Bibliography
- WHITE AD et al.: Emerging therapeutic advances for the development of second generation matrix metallopro-teinase inhibitors. Curr. Pharm. Des. (1997) 3:45–58.
- SKILES JW, MONOVICH LG, JENG AY: Matrix metallopro-teinase inhibitors for treatment of cancer. Annu. Rep. Med. Chem. (2000) 35:167–176.
- MICHAELIDES MR, CURTIN ML : Recent advances in matrix metalloproteinase inhibitors research. Curr. Pharm. Des. (1999) 5: 787–819.
- Brown, PD: Clinical studies with matrix metalloprote-inase inhibitors. APMIS (1999) 107:174–180.
- •Thorough discussion of the pharmacokinetic profiles in man along with an update on clinical trial results.
- RIZVI NA, HUMPHREY JS, NESS EA: A phase I, safety and pharmacokinetic trial of BMS-275291, a matrix metalloproteinase inhibitor (MMPI) in patients with advanced or metastatic cancer. AACR-NCI-EORTC International Conference on Molecular targets: Discovery, Development, and Clinical Validation. (Washington DC 1999).